Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application

Stock News

2025/11/03

Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.

According to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1137543318"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137543318\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137543318?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137543318","market":"hk","top_or_hot":-1,"title":"Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application","media":"Stock News","content":"<p>Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.</p>\n<p>According to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.</p>\n<p>According to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1137543318","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137543318","pubTimestamp":1762167854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0046":"生物疫苗","BK0057":"长吉图板块","BK0028":"国家队","BK0239":"医药制造","BK0075":"新三板","000661":"长春高新","BK0188":"融资融券"},"translate_title":"长春高新（000661.SZ）：GenSci134注射液获国内临床试验申请批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The domestic clinical trial application for the production and registration of GenSci134 Injection has been approved.\nAccording to the announcement, GenSci134 Injection is a Class 1 biologic drug independently developed by Jinsai Pharmaceutical for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD conditions (such as idiopathic short stature, ISS). The current application specifically targets idiopathic short stature (ISS).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}